149 related articles for article (PubMed ID: 34034269)
21. CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis.
Olfe L; von Hardenberg S; Hofmann W; Auber B; Baumann U; Beier R; Adriawan IR; Atschekzei F; Witte T; Sogkas G
Int Arch Allergy Immunol; 2023; 184(1):76-84. PubMed ID: 36273440
[TBL] [Abstract][Full Text] [Related]
22. The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.
Shouval DS; Kowalik M; Snapper SB
J Clin Immunol; 2018 Jul; 38(5):579-588. PubMed ID: 29956079
[TBL] [Abstract][Full Text] [Related]
23. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
24. Preponderance of
Siggs OM; Russell A; Singh-Grewal D; Wong M; Chan P; Craig ME; O'Loughlin T; Stormon M; Goodnow CC
Front Immunol; 2019; 10():1544. PubMed ID: 31396201
[TBL] [Abstract][Full Text] [Related]
25. CTLA-4 Haploinsufficiency Presenting as Extensive Enteropathy in a Patient With Very Early Onset Inflammatory Bowel Disease.
Tran NN; Setty M; Cham E; Chan AY; Ali S
JPGN Rep; 2021 Aug; 2(3):e099. PubMed ID: 37205940
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency.
Krone KA; Winant AJ; Vargas SO; Platt CD; Bartnikas LM; Janssen E; Lillehei C; Lee EY; Fishman MP; Casey A
Pediatr Pulmonol; 2021 Jul; 56(7):2232-2241. PubMed ID: 33710794
[TBL] [Abstract][Full Text] [Related]
27. The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.
Krausz M; Uhlmann A; Rump IC; Ihorst G; Goldacker S; Sogkas G; Posadas-Cantera S; Schmidt R; Feißt M; Alsina L; Dybedal I; Recher M; Warnatz K; Grimbacher B
Contemp Clin Trials Commun; 2022 Dec; 30():101008. PubMed ID: 36262801
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine in the treatment of primary immunodeficiency diseases.
Leiding JW; Ballow M
Curr Opin Allergy Clin Immunol; 2018 Apr; 18(2):159-166. PubMed ID: 29406361
[TBL] [Abstract][Full Text] [Related]
29. An 18-year-old woman with pulmonary nodules found to have cytotoxic T-lymphocyte-associated antigen 4 deficiency.
Al Baroudi S; Collaco JM; McGrath-Morrow S
BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31818888
[TBL] [Abstract][Full Text] [Related]
30. CTLA-4 gene mutation and multiple sclerosis: A case report and literature review.
Lin TW; Hu YC; Yang YH; Chien YH; Lee NC; Yu HH; Chiang BL; Wang LC
J Microbiol Immunol Infect; 2022 Jun; 55(3):545-548. PubMed ID: 34824019
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory Bowel Disease in Primary Immunodeficiencies.
Kelsen JR; Sullivan KE
Curr Allergy Asthma Rep; 2017 Aug; 17(8):57. PubMed ID: 28755025
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Approach to Monogenic Inflammatory Bowel Disease in Clinical Practice: A Ten-Year Multicentric Experience.
Lega S; Pin A; Arrigo S; Cifaldi C; Girardelli M; Bianco AM; Malamisura M; Angelino G; Faraci S; Rea F; Romeo EF; Aloi M; Romano C; Barabino A; Martelossi S; Tommasini A; Di Matteo G; Cancrini C; De Angelis P; Finocchi A; Bramuzzo M
Inflamm Bowel Dis; 2020 Apr; 26(5):720-727. PubMed ID: 31375816
[TBL] [Abstract][Full Text] [Related]
33. [Aggressive tumor progression during immunosuppressive therapy with abatacept].
Lapoirie J; Lefort F; Mériglier E; Rivoisy C; Contis A; Vandenhende MA; Bonnet F
Rev Med Interne; 2021 Jul; 42(7):505-508. PubMed ID: 33838949
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations.
Gremese E; Alivernini S; Ferraccioli ES; Ferraccioli G
Clin Immunol; 2020 May; 214():108395. PubMed ID: 32240819
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience.
Angelino G; De Angelis P; Faraci S; Rea F; Romeo EF; Torroni F; Tambucci R; Claps A; Francalanci P; Chiriaco M; Di Matteo G; Cancrini C; Palma P; D'Argenio P; Dall'Oglio L; Rossi P; Finocchi A
Pediatr Allergy Immunol; 2017 Dec; 28(8):801-809. PubMed ID: 28981976
[TBL] [Abstract][Full Text] [Related]
36. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
Linsley PS; Greenbaum CJ; Speake C; Long SA; Dufort MJ
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830871
[TBL] [Abstract][Full Text] [Related]
37. Coinhibitory molecules in autoimmune diseases.
Watanabe N; Nakajima H
Clin Dev Immunol; 2012; 2012():269756. PubMed ID: 22997525
[TBL] [Abstract][Full Text] [Related]
38. Early cancer of the stomach arising after successful treatment of gastric MALT lymphoma in patients with autoimmune disease.
Raderer M; Püspök A; Stummvoll G; Längle F; Chott A
Scand J Gastroenterol; 2003 Mar; 38(3):294-7. PubMed ID: 12737445
[TBL] [Abstract][Full Text] [Related]
39. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
[TBL] [Abstract][Full Text] [Related]
40. The Growing Need to Understand Very Early Onset Inflammatory Bowel Disease.
Zheng HB; de la Morena MT; Suskind DL
Front Immunol; 2021; 12():675186. PubMed ID: 34122435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
